共 50 条
Is Matrix Metalloproteinase-9 Associated with Post-Stroke Cognitive Impairment or Dementia?
被引:7
|作者:
Zhao, Jianhua
[1
]
Yang, Fangli
[1
]
Peng, Xue
[2
]
Li, Qing
[1
]
Wang, Fan
[1
]
Xu, Zhixiu
[1
]
Cai, Ruiyan
[1
]
Ji, Danxia
[3
]
Zhang, Jian
[4
]
Wang, Minghua
[1
]
Li, Qiong
[1
]
Ji, Sibei
[1
]
Li, Shaomin
[5
]
机构:
[1] Xinxiang Med Univ, Affiliated Hosp 1, Henan Joint Int Res Lab Neurorestoratol Senile De, Henan Key Lab Neurorestoratol,Dept Neurol, Xinxiang 453100, Henan, Peoples R China
[2] Jianghan Univ, Hosp Wuhan 6, Dept Neurol, Affiliated Hosp, Wuhan 430015, Hubei, Peoples R China
[3] Xinxiang Med Univ, Dept Med Record Management, Affiliated Hosp 1, Xinxiang 453100, Henan, Peoples R China
[4] Xinxiang Med Univ, Dept Imaging, Affiliated Hosp 1, Xinxiang 453100, Henan, Peoples R China
[5] Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA
关键词:
ischemic stroke;
post-stroke cognitive impairment or dementia (PSCID);
matrix metalloprotenase 9;
genetic polymorphism;
cognitive function;
METALLOPROTEINASE GENE POLYMORPHISMS;
MATRIX METALLOPROTEINASES;
HARMONIZATION STANDARDS;
CEREBROSPINAL-FLUID;
BRAIN;
STROKE;
DISEASE;
INFLAMMATION;
DYSFUNCTION;
DISORDERS;
D O I:
10.31083/j.jin2106160
中图分类号:
Q189 [神经科学];
学科分类号:
071006 ;
摘要:
Background: Matrix metalloproteinase-9 (MMP-9) is a significant protease required for synaptic plasticity, learning, and memory. Yet, the role of MMP-9 in the occurrence and development of cognitive decline after ischemic stroke is not fully understood. In this study, we used clinical data experiments to further investigate whether MMP-9 and genetic polymorphism are associated with poststroke cognitive impairment or dementia (PSCID). Materials and Methods: A total of 148 patients with PSCID confirmed by the Montreal Cognitive Assessment (MoCA) 3 months after onset (PSCID group) were included in the study. The MMP-9 rs3918242 polymorphisms were analyzed using polymerase chain reaction coupled with restriction fragment length polymorphism, and the serum level of MMP-9 was measured using enzyme-linked immunosorbent assay (ELISA). The same manipulations have been done on 169 ischemic stroke patients without cognitive impairment (NCI group) and 150 normal controls (NC group). Results: The expression level of serum MMP-9 in the PSCID group and NCI group was higher compared to the NC group, and the levels in the PSCID group were higher than that in the NCI group (all p < 0.05). Diabetes mellitus, hyperhomocysteinemia, and increased serum MMP-9 levels were the main risk factors of cognitive impairment after ischemic stroke. The serum level of MMP-9 was negatively correlated with the MoCA score, including visual-spatial executive, naming, attention, language, and delayed recall. Genetic polymorphism showed that TC genotype with MMP-9 rs3918242 and CC genotype were associated with a significantly increased risk of PSCID; moreover, the TC genotype significantly increased the risk of cognitive impairment. In the TCCC genotype of MMP-9 rs3918242, diabetes mellitus and hyperhomocysteinemia were associated with the increased risk of PSCID; also, hyperhomocysteinemia could increase the risk of cognitive impairment. Conclusions: MMP-9 level and MMP-9 rs3918242 polymorphism have an important role in the occurrence and development of post-stroke cognitive impairment or dementia (PSCID).
引用
收藏
页数:8
相关论文